Predicted protein targets (top 20)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | NPC1 | O15118 | 8/20 | 0.70 |
| ▸ | RAB9A | P51151 | 7/20 | 0.70 |
| ▸ | MAPT | P10636 | 5/20 | 0.70 |
| ▸ | SMN1; SMN2 | Q16637 | 6/20 | 0.63 |
| ▸ | TP53 | P04637 | 5/20 | 0.63 |
| ▸ | LMNA | P02545 | 1/20 | 0.63 |
| ▸ | LOXL2 | Q9Y4K0 | 1/20 | 0.61 |
| ▸ | HTT | P42858 | 1/20 | 0.53 |
| ▸ | GFER | P55789 | 1/20 | 0.53 |
| ▸ | PSMB8 | P28062 | 1/20 | 0.46 |
| ▸ | NPSR1 | Q6W5P4 | 2/20 | 0.44 |
| ▸ | USP2 | O75604 | 1/20 | 0.44 |
| ▸ | DDAH1 | O94760 | 1/20 | 0.43 |
| ▸ | ADRA2C | P18825 | 1/20 | 0.43 |
| ▸ | DRD2 | P14416 | 1/20 | 0.43 |
| ▸ | DRD4 | P21917 | 1/20 | 0.43 |
| ▸ | DRD3 | P35462 | 1/20 | 0.43 |
| ▸ | ALDH1A1 | P00352 | 4/20 | 0.43 |
| ▸ | HSD17B10 | Q99714 | 4/20 | 0.43 |
| ▸ | HPGD | P15428 | 3/20 | 0.43 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL155002 | 0.83 | MAPT (1.00) | NPC1RAB9AMAPTSMN1; SMN2TP53 | |
| SCHEMBL1420033 | 0.83 | TP53 (0.81) | NPC1RAB9AMAPTSMN1; SMN2TP53 | |
| SCHEMBL2125044 | 0.79 | MAPT (0.70) | NPC1RAB9AMAPTSMN1; SMN2TP53 | |
| SCHEMBL2125047 | 0.79 | NPC1 (0.70) | NPC1RAB9AMAPTSMN1; SMN2TP53 | |
| SCHEMBL2792617 | 0.79 | NPC1 (0.70) | NPC1RAB9AMAPTSMN1; SMN2TP53 | |
| SCHEMBL622536 | 0.79 | NPC1 (0.70) | NPC1RAB9AMAPTSMN1; SMN2TP53 | |
| SCHEMBL9642061 | 0.79 | MAPT (0.84) | NPC1RAB9AMAPTSMN1; SMN2TP53 | |
| SCHEMBL2621291 | 0.79 | MAPT (0.70) | NPC1RAB9AMAPTSMN1; SMN2TP53 | |
| SCHEMBL1786789 | 0.79 | LOXL2 (0.72) | NPC1RAB9AMAPTSMN1; SMN2TP53 | |
| Fluoride SCHEMBL7598310 | 0.79 | TP53 (0.75) | NPC1RAB9AMAPTSMN1; SMN2TP53 |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 41 patents — showing the first 20. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| EP-0072608-A2 | Process for the preparation of cephalosporin derivatives | IMPERIAL CHEMICAL INDUSTRIES PLC (GB) | 1983-02-23 | — | — | EP | claimed |
| EP-0055562-A2 | Cephalosporin derivatives | ICI PHARMA (FR) | 1982-07-07 | — | — | EP | claimed |
| US-12195469-B2 | Compounds having PDE9A inhibitory activity, and pharmaceutical uses thereof | KOREA RESEARCH INSTITUTE OF CHEMICAL TECHNOLOGY (KR) | 2025-01-14 | — | — | US | disclosed |
| EP-3892623-B1 | COMPOUNDS HAVING PDE9A INHIBITORY ACTIVITY, AND PHARMACEUTICAL USES THEREOF | KOREA RES INST CHEMICAL TECH (KR) | 2024-07-10 | — | — | EP | disclosed |
| CN-113166161-B | Compounds having PDE9A inhibiting activity and pharmaceutical uses thereof | 韩国化学研究院 | 2023-10-27 | — | — | CN | disclosed |
| US-20220024932-A1 | COMPOUNDS HAVING PDE9A INHIBITORY ACTIVITY, AND PHARMACEUTICAL USES THEREOF | KOREA RESEARCH INSTITUTE OF CHEMICAL TECHNOLOGY (KR) | 2022-01-27 | — | — | US | disclosed |
| US-20220024932-A1 | COMPOUNDS HAVING PDE9A INHIBITORY ACTIVITY, AND PHARMACEUTICAL USES THEREOF | KOREA RESEARCH INSTITUTE OF CHEMICAL TECHNOLOGY (KR) | 2022-01-27 | — | — | US | disclosed |
| EP-3892623-A1 | COMPOUNDS HAVING PDE9A INHIBITORY ACTIVITY, AND PHARMACEUTICAL USES THEREOF | Korea Research Institute of Chemical Technology (KR) | 2021-10-13 | — | — | EP | disclosed |
| CN-113166161-A | Compound with PDE9A inhibitory activity and pharmaceutical use thereof | 韩国化学研究院 | 2021-07-23 | — | — | CN | disclosed |
| US-10870661-B2 | Nitrogen-containing tricyclic derivatives having HIV replication inhibitory activity | SHIONOGI & CO., LTD. (JP) | 2020-12-22 | — | — | US | disclosed |
| EP-2772480-B2 | HIV REPLICATION INHIBITOR | SHIONOGI & CO (JP) | 2020-12-09 | — | — | EP | disclosed |
| WO-2013052190-A2 | COATING/SEALANT SYSTEMS, AQUEOUS RESINOUS DISPERSIONS, AND METHODS OF ELECTROCOATING | PRC-DESOTO INTERNATIONAL, INC. (US) | 2013-04-11 | — | — | WO | disclosed |
| US-20130065057-A1 | COATING/SEALANT SYSTEMS, AQUEOUS RESINOUS DISPERSIONS, AND METHODS OF ELECTROCOATING | PRC-DESOTO INTERNATIONAL, INC. (US) | 2013-03-14 | — | — | US | disclosed |
| US-20130065985-A1 | COATING/SEALANT SYSTEMS, AQUEOUS RESINOUS DISPERSIONS, METHODS FOR MAKING AQUEOUS RESINOUS DISPERSIONS, AND METHODS OF ELECTROCOATING | PRC-DESOTO INTERNATIONAL, INC. (US) | 2013-03-14 | — | — | US | disclosed |
| US-RE35135-E | Dental material; mixture of radical-polymerizable monomer, alpha-ketocarbonyl and aromatic amine | MITSUI PETROCHEMICAL INDUSTRIES, LTD. (JP) | 1995-12-26 | — | — | US | disclosed |
| US-5470985-A | Dye for optical recording media, photostability | KONICA CORPORATION (JP) | 1995-11-28 | — | — | US | disclosed |
| EP-0136186-B1 | PHOTOCURABLE RESIN COMPOSITION | MITSUI PETROCHEMICAL INDUSTRIES, LTD. (JP) | 1989-09-06 | — | — | EP | disclosed |
| EP-0252603-A2 | Adhesives for ceramics and processes for the bonding of ceramics using same | MITSUI SEKIYU KAGAKU KOGYO KABUSHIKI KAISHA (JP) | 1988-01-13 | — | — | EP | disclosed |
| US-4548689-A | RADICAL POLYMERIZABLE MONOMER, KETOCARBONYL COMPOUND AND MERCAPTOB | MITSUI PETROCHEMICAL INDUSTRIES, LTD. (JP) | 1985-10-22 | — | — | US | disclosed |
| US-4267343-A | CYCLIZATION AND CONDENSATION OF A BIS/BENZOXAZOYLYL/SULFIDE WITH GLYOXAL OR A GLYOXAL DERIVATIVE | CIBA-GEIGY CORPORATION (US) | 1981-05-12 | — | — | US | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (3 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-12195469-B2 | Compounds having PDE9A inhibitory activity, and pharmaceutical uses thereof | PDE9A, PDE5A, PDE3A | NPC1 1359/4885RAB9A 38/4885MAPT 3479/4885 |
| US-20220024932-A1 | COMPOUNDS HAVING PDE9A INHIBITORY ACTIVITY, AND PHARMACEUTICAL USES THEREOF | PDE9A, PDE5A, PDE3A | NPC1 1359/4885RAB9A 38/4885MAPT 3479/4885 |
| US-10870661-B2 | Nitrogen-containing tricyclic derivatives having HIV replication inhibitory activity | NR4A3, CCR3, NCOA3 | NPC1 691/4885RAB9A 3559/4885MAPT 4604/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.